YOLFTbeta
68

MegaPro Biomedical Co., Ltd

6827 · TWO · Healthcare / Biotechnology

20.20TWD+3.10 (+18.13%)

Price History

Full chart

Market Stats

Previous Close17.10
Open17.20
Day Range16.35 – 21.15
52-Week Range9.47 – 15.95
Volume2.31M
Market Cap1.05B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.39
Dividend Yield0.00%
50-Day Avg10.93
200-Day Avg11.70

About

MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs. It also develops MPB-1523, an IOP injection that is in Phase II clinical trial for use in the treatment of hepatocellular carcinoma; and MPB-1514, an iron injection that is in Phase II clinical trial for use in the treatment of iron deficiency anemia, as well as MPB-1734, an anti-cancer drug that is in preclinical trial for the treatment of malignant tumor. The company was founded in 2014 and is based in Zhubei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Jassy Wang
  • HeadquartersNo. 66, Shengyi 5th Rd., Zhubei, Taiwan, 302, Taiwan
  • Websitehttps://www.megaprobio.com

Leadership

  • Dr. Jassy WangChief Executive Officer

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-7.43M0018.00K14.00K0
Growth (%)---100.00%---22.22%-100.00%
Cost of Revenue--7.54M13.56M16.62M17.21M-
Gross Profit-7.43M-7.54M-13.56M-16.60M-17.19M-
Gross Margin-100.00%---92227.78%-122807.14%-
Operating Expense-156.76M93.44M108.19M123.89M163.00M-
Operating Income-178.34M-149.33M-100.97M-121.75M-140.49M-180.19M-119.59M
Operating Margin--2010.08%---780483.33%-1287092.86%-
EBITDA-178.34M-143.31M-81.61M-97.36M-110.34M-146.38M-103.91M
EBITDA Margin--1929.08%---612988.89%-1045607.14%-
Net Income-174.74M-148.86M-89.15M-111.72M-127.55M-164.04M-119.10M
Net Income Margin--2003.81%---708600.00%-1171721.43%-
R&D-147.03M85.56M100.92M115.95M156.91M97.81M
R&D as % of Total Revenue-1979.18%--644194.44%1120800.00%-
Interest Expense--0371.00K295.00K451.00K138.00K
Interest Expense % of Total Revenue----1638.89%3221.43%-

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-265.14M432.61M342.68M294.58M224.31M278.92M
Total Liabilities-18.77M26.77M28.34M25.51M19.96M16.28M
Total Equity-246.37M405.84M314.35M269.07M204.35M262.64M
Cash-95.20M167.71M144.22M187.88M87.68M112.28M
Total Debt--16.02M10.93M8.32M5.65M-
Net Debt--95.20M-151.69M-133.30M-179.56M-82.02M-

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-170.76M-156.30M-85.03M-82.80M-99.70M-144.17M-115.89M
Investing Cash Flow72.75M177.34M-85.29M56.41M18.78M23.81M-
Financing Cash Flow83.20M-245.00M-2.51M62.86M81.84M-
Capital Expenditure963.00K7.52M17.91M13.50M4.39M1.17M893.00K
Free Cash Flow-171.72M-163.82M-102.94M-96.30M-104.09M-145.34M-116.78M
FCF to OCF100.56%104.81%121.07%116.31%104.40%100.81%100.77%

Key Statistics & Ratios

Market Cap1.05B
Enterprise Value952.62M
Trailing P/E0.00
Forward P/E0.00
Price / Sales70226.33
Price / Book4.77
EPS-1.39
Revenue (TTM)0
Gross Profit (TTM)0
Profit Margin0.00%
Operating Margin0.00%
Return on Equity0.00%
Return on Assets0.00%
Shares Outstanding79.29M
Shares Float0
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%